Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network

Abstract

coding for the IFN-induced Mx protein in skin biopsies from patients with chilblains. 4 The Mx protein sequesters viral factors required for viral replication. 6 Furthermore, an IFN-induced transmembrane protein may inhibit coronavirus replication. This could explain why PCR tests are mostly negative in patients with suspected COVID-19 chilblains. 4 Battesti and Descamps reported that patients with moderately severe COVID-19 had high circulating levels of IFN-1. 4 We hypothesize that in young adults with efficient innate immune responses, the IFN-1 pathway inhibits the replication of SARS-CoV-2 and dampens the symptoms of COVID-19. In parallel, activation of the IFN-1 pathway might lead to manifestations that have been already described in interferonopathies like lupus (i.e. chilblains). The inhibition of viral replication might explain the negative RT-PCR and serological test results in the present case.To conclude, we report on a case of recurrent chilblains, the appearances of which coincided with the epidemic peaks in France and contact with a SARS-CoV-2-positive close relative. Our observation reinforces the hypothesis of a causal relationship between SARS-CoV-2 infection and chilblains. It also raises the question of whether this manifestation is likely to occur or recur during contact with SARS-CoV-2 components (e.g. during a mass vaccination campaign).

Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas

“…19 Finally, CD30 expression is rare and, if detected, usually weak in intensity. 6,7,20 Therefore, while we could consider brentuximab vedotin in multiply R/R disease, we acknowledge the absence of data.…”

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas

“…Consequently, CD30 is expressed in a wide range of reactive skin conditions (i.e., arthropod byte, molluscum contagiosum, etc.) [41], and notably in several systemic and cutaneous lymphomas [42]. In addition to tumor MF, CD30 is typically found in Hodgkin lymphoma, both systemic and pcALCL, and LyP.…”

“…In addition to tumor MF, CD30 is typically found in Hodgkin lymphoma, both systemic and pcALCL, and LyP. Aberrant CD30 positivity is also observed in other skin lymphomas, such as certain CBCL subtypes, and lymphoproliferative disorders (LD) in HIV-positive patients [3,32,42].…”

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

“…Approximately 32% of classic MF and 59% of transformed MF cases are CD30-positive [ 3 ]. Rare CTCL subtypes including subcutaneous panniculitis-like T-cell lymphomas, aggressive epidermotropic cytotoxic T-cell lymphomas, and NK T-cell lymphomas, among others, have also been shown to express CD30 to varying degrees [ 3 , 89 ]. Brentuximab vedotin is therefore indicated in Europe for the treatment of patients with CD30-positive CTCL who have received prior systemic therapy and in the USA for patients with C-ALCL and CD30-positive MF who have received prior systemic therapy [ 6 , 7 ] (although the exact cut-off point for determination of CD30-positivity for most CTCL is still a matter of debate [ 3 ]).…”